European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - breast neoplasms - antineoplastic agents - talzenna is indicated as monotherapy for the treatment of adult patients with germline brca1/2 mutations, who have her2-negative locally advanced or metastatic breast cancer. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.

Canada - English - Health Canada

pfizer canada ulc - talazoparib (talazoparib tosylate) - capsule - 0.25mg - talazoparib (talazoparib tosylate) 0.25mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - talazoparib (talazoparib tosylate) - capsule - 1mg - talazoparib (talazoparib tosylate) 1mg - antineoplastic agents

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - talazoparib 0.25 mg/1 cap - 0.25 mg/1 cap

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - talazoparib 1 mg/1 cap - 1 mg/1 cap

Kenya - English - Pharmacy and Poisons Board

talazoparib - capsule, hard - 0.25 mg - talazoparib

Kenya - English - Pharmacy and Poisons Board

talazoparib - capsule, hard - 1 mg - talazoparib

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - talazoparib tosylate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - talazoparib tosylate -